India has made significant progress in terms of self-reliance in pharmaceutical products. Prices for indigenously manufactured drugs are the lowest in the world.
The success story of the pharmaceutical sector stems from its reliance on reverse engineering – a process that has allowed quick replication of new drugs at a low cost – to make and sell generic drugs.
This was possible thanks to the overall policy environment created by the Patents Act, 1970, which allowed only process patents.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员。
Priti Suri is the proprietor of PSA. Nikita Ved is an associate.
Legal Counsellors
E601 Gauri Sadan, 5 Hailey Road
New Delhi – 110 00 India
Tel: +91 11 4350 0500
Fax: +91 11 4350 0502
www.psalegal.com
Email: p.suri@psalegal.com